Home > Publications database > Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma. > print

001     298594
005     20250511020418.0
024 7 _ |a 10.1158/2643-3230.BCD-24-0178
|2 doi
024 7 _ |a pmid:39913291
|2 pmid
024 7 _ |a 2643-3230
|2 ISSN
024 7 _ |a 2643-3249
|2 ISSN
024 7 _ |a altmetric:174083404
|2 altmetric
037 _ _ |a DKFZ-2025-00304
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Liebers, Nora
|0 P:(DE-He78)31f8eac7b031fdafb391c06ba0ea992e
|b 0
|e First author
245 _ _ |a Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma.
260 _ _ |a Philadelphia, PA
|c 2025
|b American Association for Cancer Research
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1746604547_3748
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B340# / 2025 May 5;6(3):182-190
520 _ _ |a Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 r/r MCL patients aged ≥50 years treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (out of 272) r/r MCL patients who underwent alloHCT using data from the EBMT registry. Median follow-up time was 36.5 and 34.1 months for the brexu-cel and matched alloHCT cohort, respectively. Brexu-cel patients had a significantly higher overall survival (OS, 81.3% vs 59.2%, HR: 0.39, p=0.004) and lower non-relapse mortality (3.6% vs 21.2%, p=0.015) one year after treatment. Chronic graft-vs-host disease occurred in 26.9% of alloHCT patients within the first year. However, long-term progression-free survival and OS remain comparable. Despite limitations of this non-randomized study, it indicates a superior safety profile for brexu-cel in r/r MCL.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Boumendil, Ariane
|0 0000-0002-2552-0542
|b 1
700 1 _ |a Finel, Hervé
|b 2
700 1 _ |a Edelmann, Dominic
|0 P:(DE-He78)92820b4867c955a04f642707ecf35b40
|b 3
|u dkfz
700 1 _ |a Kobbe, Guido
|0 0000-0002-9745-8813
|b 4
700 1 _ |a Baermann, Ben-Niklas
|0 0009-0000-1699-9478
|b 5
700 1 _ |a Serroukh, Yasmina
|0 0000-0001-8751-5725
|b 6
700 1 _ |a Blaise, Didier
|0 0000-0002-5684-9447
|b 7
700 1 _ |a Beelen, Dietrich Wilhelm
|0 0000-0001-5050-220X
|b 8
700 1 _ |a Solano, Carlos
|0 0000-0003-3702-0817
|b 9
700 1 _ |a Itälä-Remes, Maija
|0 0000-0001-5844-1632
|b 10
700 1 _ |a van Meerten, Tom
|0 0000-0002-5581-6950
|b 11
700 1 _ |a Choi, Goda
|0 0009-0007-2067-9750
|b 12
700 1 _ |a Schmidt, Susanne A C
|0 0009-0001-5941-3673
|b 13
700 1 _ |a Kröger, Nicolaus
|0 0000-0001-5103-9966
|b 14
700 1 _ |a Byrne, Jenny
|0 0009-0004-7576-2787
|b 15
700 1 _ |a Tudesq, Jean-Jacques
|0 0000-0003-4879-8106
|b 16
700 1 _ |a Ossami Saidy, Anna
|0 0000-0001-6722-0065
|b 17
700 1 _ |a Nunes, Ana
|0 0009-0004-7481-9550
|b 18
700 1 _ |a Siddiqi, Rubina
|0 0000-0003-0244-1531
|b 19
700 1 _ |a Baro, Elande
|0 0009-0004-8566-6828
|b 20
700 1 _ |a Zheng, Dan
|0 0009-0005-6516-1723
|b 21
700 1 _ |a Kloos, Ioana
|0 0009-0004-3243-8450
|b 22
700 1 _ |a Dreger, Peter
|0 0000-0002-7429-8570
|b 23
700 1 _ |a Sureda, Anna
|0 0000-0002-1238-6970
|b 24
700 1 _ |a Glass, Bertram
|0 0009-0000-0816-688X
|b 25
700 1 _ |a Dietrich, Sascha
|b 26
773 _ _ |a 10.1158/2643-3230.BCD-24-0178
|0 PERI:(DE-600)3028898-8
|n 3
|p 182-190
|t Blood cancer discovery
|v 6
|y 2025
|x 2643-3230
909 C O |p VDB
|o oai:inrepo02.dkfz.de:298594
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)31f8eac7b031fdafb391c06ba0ea992e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)92820b4867c955a04f642707ecf35b40
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BLOOD CANCER DISCOV : 2022
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2024-12-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b BLOOD CANCER DISCOV : 2022
|d 2024-12-06
920 1 _ |0 I:(DE-He78)B340-20160331
|k B340
|l Translationale Medizinische Onkologie
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 1
920 0 _ |0 I:(DE-He78)B340-20160331
|k B340
|l Translationale Medizinische Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B340-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21